Febuxostat and agranulocytosis

An article in *Gebu 2015; 49: 46-47* concluded that although febuxostat effectively lowers serum uric acid levels, there was insufficient evidence for its efficacy in terms of clinical outcome measures and safety, and insufficient evidence to introduce this drug as a routine maintenance therapy for chronic gout. In addition to its high cost, the safety profile of febuxostat is another argument for reticence in prescribing this drug.

References*


*The literature refers to the Dutch text*

Copyright © 2020 Ge-Bu. Alle rechten voorbehouden. | [https://www.ge-bu.nl](https://www.ge-bu.nl)